181 related articles for article (PubMed ID: 16781788)
1. Effects of omega-3 polyunsaturated fatty acids on metabolically active hormones in patients post-myocardial infarction.
Patel JV; Lee KW; Tomson J; Dubb K; Hughes EA; Lip GY
Int J Cardiol; 2007 Jan; 115(1):42-5. PubMed ID: 16781788
[TBL] [Abstract][Full Text] [Related]
2. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction.
Lee KW; Blann AD; Lip GY
Thromb Res; 2006; 118(3):305-12. PubMed ID: 16154181
[TBL] [Abstract][Full Text] [Related]
3. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Rupp H
Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
[TBL] [Abstract][Full Text] [Related]
4. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Donadio JV; Bergstralh EJ; Bibus DM; Grande JP
Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
[TBL] [Abstract][Full Text] [Related]
5. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Burns T; Maciejewski SR; Hamilton WR; Zheng M; Mooss AN; Hilleman DE
Pharmacotherapy; 2007 May; 27(5):633-8. PubMed ID: 17461697
[TBL] [Abstract][Full Text] [Related]
6. Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects.
Guebre-Egziabher F; Rabasa-Lhoret R; Bonnet F; Bastard JP; Desage M; Skilton MR; Vidal H; Laville M
Eur J Clin Nutr; 2008 Nov; 62(11):1287-93. PubMed ID: 17700650
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin is involved in the protective effect of DHEA against metabolic risk in aged rats.
Pérez-de-Heredia F; Sánchez J; Priego T; Nicolás F; Portillo Mdel P; Palou A; Zamora S; Garaulet M
Steroids; 2008 Oct; 73(11):1128-36. PubMed ID: 18534650
[TBL] [Abstract][Full Text] [Related]
8. Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.
Kar S
Am J Ther; 2014; 21(1):56-66. PubMed ID: 21975796
[TBL] [Abstract][Full Text] [Related]
9. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study.
Saifullah A; Watkins BA; Saha C; Li Y; Moe SM; Friedman AN
Nephrol Dial Transplant; 2007 Dec; 22(12):3561-7. PubMed ID: 17623719
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men.
Trøseid M; Arnesen H; Hjerkinn EM; Seljeflot I
Metabolism; 2009 Nov; 58(11):1543-9. PubMed ID: 19595382
[TBL] [Abstract][Full Text] [Related]
11. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients.
Rasic-Milutinovic Z; Perunicic G; Pljesa S; Gluvic Z; Sobajic S; Djuric I; Ristic D
Ren Fail; 2007; 29(3):321-9. PubMed ID: 17497447
[TBL] [Abstract][Full Text] [Related]
12. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions.
O'Keefe JH; Abuissa H; Sastre A; Steinhaus DM; Harris WS
Am J Cardiol; 2006 Apr; 97(8):1127-30. PubMed ID: 16616012
[TBL] [Abstract][Full Text] [Related]
13. Relationship of omega-3 fatty acid supplementation to plasma lipid peroxidation in predialysis patients with hypertriglyceridaemia.
Richard MJ; Sirajeddine MK; Cordonnier D; Tricot F; Foulon T; Mouneimne A; Maurizi J
Eur J Med; 1993 Jan; 2(1):15-8. PubMed ID: 8257999
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse.
Mustad VA; Demichele S; Huang YS; Mika A; Lubbers N; Berthiaume N; Polakowski J; Zinker B
Metabolism; 2006 Oct; 55(10):1365-74. PubMed ID: 16979408
[TBL] [Abstract][Full Text] [Related]
15. Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients.
Hamaad A; Kaeng Lee W; Lip GY; MacFadyen RJ
Cardiovasc Drugs Ther; 2006 Oct; 20(5):359-64. PubMed ID: 17089085
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
Hogg RJ; Fitzgibbons L; Atkins C; Nardelli N; Bay RC;
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1167-72. PubMed ID: 17699343
[TBL] [Abstract][Full Text] [Related]
17. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
Bays H
Am J Cardiol; 2006 Aug; 98(4A):71i-76i. PubMed ID: 16919519
[TBL] [Abstract][Full Text] [Related]
18. Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals.
Chin HJ; Fu YY; Ahn JM; Na KY; Kim YS; Kim S; Chae DW
Nephrol Dial Transplant; 2010 May; 25(5):1450-7. PubMed ID: 20042400
[TBL] [Abstract][Full Text] [Related]
19. Effect of omega 3 and omega 6 fatty acid intakes from diet and supplements on plasma fatty acid levels in the first 3 years of life.
Hoyos C; Almqvist C; Garden F; Xuan W; Oddy WH; Marks GB; Webb KL
Asia Pac J Clin Nutr; 2008; 17(4):552-7. PubMed ID: 19114389
[TBL] [Abstract][Full Text] [Related]
20. Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men.
Yusof HM; Miles EA; Calder P
Prostaglandins Leukot Essent Fatty Acids; 2008 Mar; 78(3):219-28. PubMed ID: 18403189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
